TransCode Therapeutics Inc (NASDAQ:RNAZ)’s traded shares stood at 0.68 million during the last session, with the company’s beta value hitting 1.00. At the close of trading, the stock’s price was $9.86, to imply a decrease of -13.28% or -$1.51 in intraday trading. The RNAZ share’s 52-week high remains $66.33, putting it -572.72% down since that peak but still an impressive 73.02% since price per share fell to its 52-week low of $2.66. The company has a valuation of $6.87M, with an average of 8.46 million shares in intraday trading volume over the past 10 days and average of 1.63 million shares over the past 3 months.
TransCode Therapeutics Inc (NASDAQ:RNAZ) trade information
After registering a -13.28% downside in the last session, TransCode Therapeutics Inc (RNAZ) has traded red over the past five days. The 5-day price performance for the stock is 30.42%, and 173.13% over 30 days. With these gigs, the year-to-date price performance is 192.58%. Short interest in TransCode Therapeutics Inc (NASDAQ:RNAZ) saw shorts transact 0.74 million shares and set a 0.5 days time to cover.
Revenue forecast for the current quarter as set by 1 analysts is 300k.
An assessment of the company’s 5-year growth patterns shows that annual earnings shrunk an estimated -28.81% for the past 5-year period. While 2025 is set for a 95.41% return in earnings, projections for the next 5 years are at 78.85% annually.
RNAZ Dividends
TransCode Therapeutics Inc has its next earnings report out in March. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
TransCode Therapeutics Inc (NASDAQ:RNAZ)’s Major holders
TransCode Therapeutics Inc insiders hold 0.01% of total outstanding shares, with institutional holders owning 1.99% of the shares at 1.99% float percentage. In total, 1.99% institutions holds shares in the company.
We also have Fidelity Extended Market Index Fund and Fidelity Total Market Index Fund as the top two Mutual Funds with the largest holdings of the TransCode Therapeutics Inc (RNAZ) shares. Going by data provided on Nov 30, 2024 , Fidelity Extended Market Index Fund holds roughly 2.89 shares. This is just over 0.41% of the total shares, with a market valuation of $28465.0. Data from the same date shows that the other fund manager holds a little less at 1.18, or 0.17% of the shares, all valued at about 11634.0.
